Therapy with cyclosporine in psoriatic arthritis (Q41587460)

4 October 2017

1 reference

title

Therapy with cyclosporine in psoriatic arthritis (English)

1 reference

4 October 2017

1 reference

2

1 reference

4 October 2017

Olivieri I

1

1 reference

4 October 2017

Cantini F

3

1 reference

4 October 2017

Macchioni L

4

1 reference

4 October 2017

Padula A

5

1 reference

4 October 2017

Niccoli L

6

1 reference

4 October 2017

Boiardi L

7

1 reference

4 October 2017

Portioli I

8

1 reference

4 October 2017

language of work or name

1 reference

1 August 1997

1 reference

Seminars in Arthritis and Rheumatism

4 October 2017

published in

1 reference

4 October 2017

volume

27

1 reference

4 October 2017

issue

1

1 reference

4 October 2017

page(s)

36-43

1 reference

Psoriatic arthritis. Follow-up study

4 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Psoriatic arthritis: A clinical, immunologic and HLA study of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Cyclosporine improves psoriasis in a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Multisystem crystalline deposits. Primary hyperoxaluria

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Cyclosporin A in psoriatic arthritis: an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

The immunology of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated Response

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

T cells involved in psoriasis vulgaris belong to the Th1 subset

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Use of the polymerase chain reaction in quantification of interleukin 8 mRNA in minute epidermal samples

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Lipopolysaccharide-stimulated human monocytes secrete, apart from neutrophil-activating peptide 1/interleukin 8, a second neutrophil-activating protein. NH2-terminal amino acid sequence identity with melanoma growth stimulatory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Psoriasin: a novel chemotactic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Abnormal helper-inducer/suppressor-inducer T-cell subset distribution and T-cell activation status are common to all types of chronic synovitis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Abnormal T-cell function in patients with psoriatic arthritis: evidence for decreased interleukin 2 production

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Soluble tumor necrosis factor receptors in human inflammatory synovial fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

NFATp, a cyclosporin-sensitive transcription factor implicated in cytokine gene induction.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Evidence that cyclosporine inhibits cell-mediated immunity primarily at the level of the T lymphocyte rather than the accessory cell

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Effect of cyclosporine A on the regulation of Ia antigen keratinocytes expression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Cyclosporin A inhibits the release of histamine and peptide leukotriene C4 from human lung mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Combination therapy with cyclosporin in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

Radiologic assessment as an outcome measure in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2897%2980035-2

7 January 2021

10.1016/S0049-0172(97)80035-2

Identifiers

DOI

1 reference

4 October 2017

1 reference